This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brockmöller, J. Articles by Roots, I. Search for Related Content PubMed PubMed Citation Articles by Brockmöller, J. Articles by Roots, I.

Combined Analysis of Inherited Polymorphisms in Arylamine N-Acetyltransferase 2, Glutathione S-Transferases M1 and T1, Microsomal Epoxide Hydrolase, and Cytochrome P450 Enzymes as Modulators of Bladder Cancer Risk

Institut für Klinische Pharmakologie, Universitätklinikum Charité, Humboldt-Universität zu Berlin, Schumannstrasse 20/21, D-10098 Berlin, Germany

Foreign compound-metabolizing enzymes may modify the risk of chemically induced cancer. We wanted to examine enzymes with putative relevance in urinary bladder cancer using molecular genetic analyses of heritably polymorphic enzymes. Arylamine N-acetyltransferase (NAT2); glutathione S-transferases (GSTs) M1 and T1; microsomal epoxide hydrolase; and cytochrome P-450 enzymes (CYP) 1A1, 2C19, 2D6, and 2E1 were analyzed in 374 cases and in 373 controls in a hospital-based case-control study in Berlin. Slow acetylation was a significant risk factor in heavy smokers [odds ratio (OR), 2.7; 95% confidence interval (CI), 1.0–7.4], with the greatest risk noted for the allele NAT2*5B. GSTM1 deficiency was a risk factor independent of smoking and occupation (OR, 1.6; CI, 1.2–2.2). GSTT1 was associated with cancer risk in the nonsmoker subgroup (OR, 2.6; CI, 1.1–6.0). The two amino acid polymorphisms that are known in microsomal epoxide hydrolase were not associated with bladder cancer risk. CYP2D6 activity was rejected as a risk factor by phenotyping and by detailed molecular genetic analyses. CYP2C19 may have a role in bladder cancer risk, but polymorphisms in CYP1A1 and 2E1 had no statistically significant impact. Deficiencies in both NAT2 and GSTM1 failed to show significant synergistic or antagonistic interactions. In conclusion, molecular genetic analysis of a large sample specified the increased bladder cancer risk of those who are deficient in NAT2 and GSTM1; the other traits proved to be of minor impact.

¹ To whom requests for reprints should be addressed. Phone: 49-30-2802 8912; Fax: 49-30-2802 5153.

Received 2/ 9/96. Accepted 6/28/96.

This article has been cited by other articles:

				L. FONTANA, L. DELORT, L. JOUMARD, N. RABIAU, R. BOSVIEL, S. SATIH, L. GUY, J.-P. BOITEUX, Y.-J. BIGNON, A. CHAMOUX, et al. Genetic Polymorphisms in CYP1A1, CYP1B1, COMT, GSTP1 and NAT2 Genes and Association with Bladder Cancer Risk in a French Cohort Anticancer Res, May 1, 2009; 29(5): 1631 - 1635. [Abstract] [Full Text] [PDF]

				H. Wu, L. Dombrovsky, W. Tempel, F. Martin, P. Loppnau, G. H. Goodfellow, D. M. Grant, and A. N. Plotnikov Structural Basis of Substrate-binding Specificity of Human Arylamine N-Acetyltransferases J. Biol. Chem., October 12, 2007; 282(41): 30189 - 30197. [Abstract] [Full Text] [PDF]

				S. Sanderson, G. Salanti, and J. Higgins Joint Effects of the N-Acetyltransferase 1 and 2 (NAT1 and NAT2) Genes and Smoking on Bladder Carcinogenesis: A Literature-based Systematic HuGE Review and Evidence Synthesis Am. J. Epidemiol., October 1, 2007; 166(7): 741 - 751. [Abstract] [Full Text] [PDF]

				Y. Chen, Y. Bai, J. Yuan, W. Chen, J. Sun, H. Wang, H. Liang, L. Guo, X. Yang, H. Tan, et al. Association of Polymorphisms in AhR, CYP1A1, GSTM1, and GSTT1 Genes with Levels of DNA Damage in Peripheral Blood Lymphocytes among Coke-Oven Workers. Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1703 - 1707. [Abstract] [Full Text] [PDF]

				L. F. Masson, L. Sharp, S. C. Cotton, and J. Little Cytochrome P-450 1A1 Gene Polymorphisms and Risk of Breast Cancer: A HuGE Review Am. J. Epidemiol., May 15, 2005; 161(10): 901 - 915. [Abstract] [Full Text] [PDF]

				K. Iida, K. Itoh, Y. Kumagai, R. Oyasu, K. Hattori, K. Kawai, T. Shimazui, H. Akaza, and M. Yamamoto Nrf2 Is Essential for the Chemopreventive Efficacy of Oltipraz against Urinary Bladder Carcinogenesis Cancer Res., September 15, 2004; 64(18): 6424 - 6431. [Abstract] [Full Text] [PDF]

				R Bachus, K Neubert, I Roots, J Prudlo, J Brockmoller, and A C Ludolph Polymorphisms of toxifying and detoxifying hepatic enzymes in amyotrophic lateral sclerosis J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1161 - 1161. [Full Text] [PDF]

				A. Johne, I. Roots, and J. Brockmoller A Single Nucleotide Polymorphism in the Human H-ras Proto-oncogene Determines the Risk of Urinary Bladder Cancer Cancer Epidemiol. Biomarkers Prev., January 1, 2003; 12(1): 68 - 70. [Abstract] [Full Text] [PDF]

				C. Sachse, G. Smith, M. J.V. Wilkie, J. H. Barrett, R. Waxman, F. Sullivan, D. Forman, D. T. Bishop, and C.R. Wolf A pharmacogenetic study to investigate the role of dietary carcinogens in the etiology of colorectal cancer Carcinogenesis, November 1, 2002; 23(11): 1839 - 1850. [Abstract] [Full Text] [PDF]

				P. G. Shields Tobacco Smoking, Harm Reduction, and Biomarkers J Natl Cancer Inst, October 2, 2002; 94(19): 1435 - 1444. [Abstract] [Full Text] [PDF]

				J. Chang-Claude, S. Kropp, B. Jager, H. Bartsch, and A. Risch Differential Effect of NAT2 on the Association between Active and Passive Smoke Exposure and Breast Cancer Risk Cancer Epidemiol. Biomarkers Prev., August 1, 2002; 11(8): 698 - 704. [Abstract] [Full Text] [PDF]

				L. S. Engel, E. Taioli, R. Pfeiffer, M. Garcia-Closas, P. M. Marcus, Q. Lan, P. Boffetta, P. Vineis, H. Autrup, D. A. Bell, et al. Pooled Analysis and Meta-analysis of Glutathione S-Transferase M1 and Bladder Cancer: A HuGE Review Am. J. Epidemiol., July 15, 2002; 156(2): 95 - 109. [Abstract] [Full Text] [PDF]

				S. C. Buch, P. N. Notani, and R. A. Bhisey Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population Carcinogenesis, May 1, 2002; 23(5): 803 - 807. [Abstract] [Full Text] [PDF]

				S. Garte, L. Gaspari, A.-K. Alexandrie, C. Ambrosone, H. Autrup, J. L. Autrup, H. Baranova, L. Bathum, S. Benhamou, P. Boffetta, et al. Metabolic Gene Polymorphism Frequencies in Control Populations Cancer Epidemiol. Biomarkers Prev., December 1, 2001; 10(12): 1239 - 1248. [Abstract] [Full Text] [PDF]

				P. Vineis, D. Marinelli, H. Autrup, J. Brockmoller, I. Cascorbi, A. K. Daly, K. Golka, H. Okkels, A. Risch, N. Rothman, et al. Current Smoking, Occupation, N-Acetyltransferase-2 and Bladder Cancer: A Pooled Analysis of Genotype-based Studies Cancer Epidemiol. Biomarkers Prev., December 1, 2001; 10(12): 1249 - 1252. [Abstract] [Full Text] [PDF]

				C. Chen, S. Ricks, D. R. Doody, E.D. Fitzgibbons, P. L. Porter, and S. M. Schwartz N-Acetyltransferase 2 polymorphisms, cigarette smoking and alcohol consumption, and oral squamous cell cancer risk Carcinogenesis, December 1, 2001; 22(12): 1993 - 1999. [Abstract] [Full Text] [PDF]

				C. M. Ulrich, J. Bigler, J. A. Whitton, R. Bostick, L. Fosdick, and J. D. Potter Epoxide Hydrolase Tyr113His Polymorphism Is Associated with Elevated Risk of Colorectal Polyps in the Presence of Smoking and High Meat Intake Cancer Epidemiol. Biomarkers Prev., August 1, 2001; 10(8): 875 - 882. [Abstract] [Full Text] [PDF]

				I. Cascorbi, I. Roots, and J. Brockmoller Association of NAT1 and NAT2 Polymorphisms to Urinary Bladder Cancer: Significantly Reduced Risk in Subjects with NAT1*10 Cancer Res., July 1, 2001; 61(13): 5051 - 5056. [Abstract] [Full Text] [PDF]

				X. Wu, K. Gwyn, C. I. Amos, N. Makan, W. K. Hong, and M. R. Spitz The association of microsomal epoxide hydrolase polymorphisms and lung cancer risk in African-Americans and Mexican-Americans Carcinogenesis, June 1, 2001; 22(6): 923 - 928. [Abstract] [Full Text] [PDF]

				M-W Yu, C-I Pai, S-Y Yang, T-J Hsiao, H-C Chang, S-M Lin, Y-F Liaw, P-J Chen, and C-J Chen Role of N-acetyltransferase polymorphisms in hepatitis B related hepatocellular carcinoma: impact of smoking on risk Gut, November 1, 2000; 47(5): 703 - 709. [Abstract] [Full Text] [PDF]

				L.E. Johns and R.S. Houlston Glutathione S-transferase {micro}1 (GSTM1) status and bladder cancer risk: a meta-analysis Mutagenesis, September 1, 2000; 15(5): 399 - 404. [Abstract] [Full Text] [PDF]

				N. Malats, A.-M. Camus-Radon, F. Nyberg, W. Ahrens, V. Constantinescu, A. Mukeria, S. Benhamou, H. Batura-Gabryel, I. Bruske-Hohlfeld, L. Simonato, et al. Lung Cancer Risk in Nonsmokers and GSTM1 and GSTT1 Genetic Polymorphism Cancer Epidemiol. Biomarkers Prev., August 1, 2000; 9(8): 827 - 833. [Abstract] [Full Text]

				M. Krajinovic, C. Richer, H. Sinnett, D. Labuda, and D. Sinnett Genetic Polymorphisms of N-Acetyltransferases 1 and 2 and Gene-Gene Interaction in the Susceptibility to Childhood Acute Lymphoblastic Leukemia Cancer Epidemiol. Biomarkers Prev., June 1, 2000; 9(6): 557 - 562. [Abstract] [Full Text]

				P. M. Marcus, R. B. Hayes, P. Vineis, M. Garcia-Closas, N. E. Caporaso, H. Autrup, R. A. Branch, J. Brockmöller, T. Ishizaki, A. E. Karakaya, et al. Cigarette Smoking, N-Acetyltransferase 2 Acetylation Status, and Bladder Cancer Risk: A Case-Series Meta-analysis of a Gene-Environment Interaction Cancer Epidemiol. Biomarkers Prev., May 1, 2000; 9(5): 461 - 467. [Abstract] [Full Text]

				K. F. Windmill, A. Gaedigk, P. de la M. Hall, H. Samaratunga, D. M. Grant, and M. E. McManus Localization of N-Acetyltransferases NAT1 and NAT2 in Human Tissues Toxicol. Sci., March 1, 2000; 54(1): 19 - 29. [Abstract] [Full Text] [PDF]

				I. Cascorbi, S. Henning, J. Brockmöller, J. Gephart, C. Meisel, J. M. Müller, R. Loddenkemper, and I. Roots Substantially Reduced Risk of Cancer of the Aerodigestive Tract in Subjects with Variant -463A of the Myeloperoxidase Gene Cancer Res., February 1, 2000; 60(3): 644 - 649. [Abstract] [Full Text]

				H. Bartsch, U. Nair, A. Risch, M. Rojas, H. Wikman, and K. Alexandrov Genetic Polymorphism of CYP Genes, Alone or in Combination, as a Risk Modifier of Tobacco-related Cancers Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 3 - 28. [Abstract] [Full Text]

				D. W. Hein, M. A. Doll, A. J. Fretland, M. A. Leff, S. J. Webb, G. H. Xiao, U.-S. Devanaboyina, N. A. Nangju, and Y. Feng Molecular Genetics and Epidemiology of the NAT1 and NAT2 Acetylation Polymorphisms Cancer Epidemiol. Biomarkers Prev., January 1, 2000; 9(1): 29 - 42. [Abstract] [Full Text]

				M. Rojas, I. Cascorbi, K. Alexandrov, E. Kriek, G. Auburtin, L. Mayer, A. Kopp-Schneider, I. Roots, and H. Bartsch Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism Carcinogenesis, January 1, 2000; 21(1): 35 - 41. [Abstract] [Full Text] [PDF]

				M. Sato, T. Sato, T. Izumo, and T. Amagasa Genetic polymorphism of drug-metabolizing enzymes and susceptibility to oral cancer Carcinogenesis, October 1, 1999; 20(10): 1927 - 1931. [Abstract] [Full Text] [PDF]

				H. Baranova, M. Canis, T. Ivaschenko, E. Albuisson, R. Bothorishvilli, V. Baranov, P. Malet, and M.A. Bruhat Possible involvement of arylamine N-acetyltransferase 2, glutathione S-transferases M1 and T1 genes in the development of endometriosis Mol. Hum. Reprod., July 1, 1999; 5(7): 636 - 641. [Abstract] [Full Text] [PDF]

				V. Nazar-Stewart, T. L. Vaughan, R. D. Burt, C. Chen, M. Berwick, and G. M. Swanson Glutathione S-Transferase M1 and Susceptibility to Nasopharyngeal Carcinoma Cancer Epidemiol. Biomarkers Prev., June 1, 1999; 8(6): 547 - 551. [Abstract] [Full Text]

				S. Longuemaux, C. Delomenie, C. Gallou, A. Mejean, M. Vincent-Viry, R. Bouvier, D. Droz, R. Krishnamoorthy, M.-M. Galteau, C. Junien, et al. Candidate Genetic Modifiers of Individual Susceptibility to Renal Cell Carcinoma: A Study of Polymorphic Human Xenobiotic-metabolizing Enzymes Cancer Res., June 1, 1999; 59(12): 2903 - 2908. [Abstract] [Full Text] [PDF]